普昂医疗（920069）：北交所新股申购策略报告之一百六十七：专精糖尿病护理与微创介入类医疗器械-20260317

Investment Rating - The report recommends an active participation in the company's IPO, indicating a favorable investment outlook with a PE (TTM) of 10.83, which is significantly lower than the industry average [24]. Core Insights - The company specializes in diabetes care and minimally invasive medical devices, with a strong market position in insulin pen needles and a successful expansion into high-growth minimally invasive intervention sectors [4][24]. - The company has shown steady revenue growth, with projected revenue of 318 million yuan in 2024, reflecting a CAGR of +14.74% over the past three years [10][24]. - The global demand for diabetes treatment is expected to continue growing, with the number of adult diabetes patients projected to reach 783 million by 2045 [16][17]. Summary by Sections 1. Company Overview - Established in 2013, the company focuses on the research, production, and sales of diabetes care and minimally invasive medical devices, with products sold in over 70 countries [4][9]. - The core product, insulin pen needles, has a notable market share, with projected sales of 1.175 billion units in 2024, increasing from 7.52% to 11.78% market share from 2022 to 2024 [4][9]. 2. Issuance Plan - The IPO will utilize a direct pricing method, with an issue price of 18.38 yuan per share and an initial issuance scale of 10.5828 million shares, representing 20% of the total post-issue share capital [14][15]. - The expected circulation ratio post-issue is 27.93%, with a moderate threshold for online subscription [14][15]. 3. Industry Situation - The demand for diabetes treatment is on the rise, with the prevalence of diabetes in China increasing from 8.8% in 2011 to 10.6% in 2021, and projected to reach 11.8% by 2030 [16][17]. - The industry is witnessing a trend towards high-end and intelligent product upgrades in minimally invasive medical devices [16][17]. 4. Competitive Advantages - The company has a strong R&D advantage, being one of the first domestic firms to introduce safety automatic self-destroying injection needles [18]. - It also boasts intelligent production capabilities, ensuring rapid industrialization of new products through advanced manufacturing technologies [18]. - The company has established a broad customer base across multiple continents, enhancing its market reputation and ability to respond to global demand [18]. 5. Comparable Companies - The company has a higher gross margin of 49.44% compared to its peers, indicating superior profitability [23].